Evaluating the role of Section 1115 waivers on Medicaid coverage and utilization of opioid agonist therapy among substance use treatment admissions

Kayla N. Tormohlen, Noa Krawczyk, Kenneth A. Feder, Kira E. Riehm, Rosa M. Crum, Ramin Mojtabai

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To examine the impact of Section 1115 waivers on Medicaid coverage and opioid agonist therapy (OAT) utilization among substance use treatment admissions. Data Source: Treatment Episode Data Set-Admissions (TEDS-A) (2001-2012). Study Design: We examined effects of 1115 waiver implementation on proportions of substance use treatment admissions with Medicaid and receiving OAT, using random intercept linear regression. Principal Findings: 1115 waiver implementation was associated with an average of a 6 percentage point increase in proportion of all admissions with Medicaid, and 4 percentage point increase among opioid outpatient admissions. Implementation was not associated with change in proportion of opioid outpatient admissions receiving OAT. Conclusions: 1115 waivers influence Medicaid coverage among substance use treatment admissions. The findings improve our understanding of how state policies impact substance use treatment utilization.

Original languageEnglish (US)
Pages (from-to)232-238
Number of pages7
JournalHealth services research
Volume55
Issue number2
DOIs
StatePublished - Apr 1 2020

Keywords

  • Section 1115 waiver
  • medicaid
  • opioid agonist therapy
  • opioid use treatment
  • substance use treatment

ASJC Scopus subject areas

  • Health Policy

Fingerprint Dive into the research topics of 'Evaluating the role of Section 1115 waivers on Medicaid coverage and utilization of opioid agonist therapy among substance use treatment admissions'. Together they form a unique fingerprint.

Cite this